Precision drug delivery to the central nervous system using engineered nanoparticles
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Valori, C. F., Possenti, A., Brambilla, L. & Rossi, D. Challenges and opportunities of targeting astrocytes to halt neurodegenerative disorders. Cells 10, 2019 (2021).10.3390/cells10082019 ↗
2. Prabakaran, A. et al. Nose-to-brain drug delivery for the treatment of Alzheimer’s disease: current advancements and challenges. Expert Opin. Drug Deliv. 19, 87–102 (2022).10.1080/17425247.2022.2029845 ↗
3. Markowicz-Piasecka, M. et al. Current approaches to facilitate improved drug delivery to the central nervous system. Eur. J. Pharm. Biopharm. 181, 249–262 (2022).10.1016/j.ejpb.2022.11.003 ↗
4. Doody, R. S. et al. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N. Engl. J. Med. 369, 341–350 (2013).10.1056/NEJMoa1210951 ↗
5. Imbimbo, B. P. & Giardina, G. A. M. γ-Secretase inhibitors and modulators for the treatment of Alzheimer’s disease: disappointments and hopes. Curr. Top. Med. Chem. 11, 1555–1570 (2011).10.2174/156802611795860942 ↗
6. Kouhi, A. et al. Brain disposition of antibody-based therapeutics: dogma, approaches and perspectives. Int. J. Mol. Sci. 22, 6442 (2021).10.3390/ijms22126442 ↗
7. Chang, H.-Y. et al. Brain pharmacokinetics of anti-transferrin receptor antibody affinity variants in rats determined using microdialysis. mAbs 13, 1874121 (2021).10.1080/19420862.2021.1874121 ↗
8. Keiser, M. S. et al. Toxicity after AAV delivery of RNAi expression constructs into nonhuman primate brain. Nat. Med. 27, 1982–1989 (2021).10.1038/s41591-021-01522-3 ↗
9. Ling, Q., Herstine, J. A., Bradbury, A. & Gray, S. J. AAV-based in vivo gene therapy for neurological disorders. Nat. Rev. Drug Discov. 22, 789–806 (2023).10.1038/s41573-023-00766-7 ↗
10. Lee, H. et al. Multi-omic analysis of selectively vulnerable motor neuron subtypes implicates altered lipid metabolism in ALS. Nat. Neurosci. 24, 1673–1685 (2021).10.1038/s41593-021-00944-z ↗
11. Herb, B. R. et al. Single-cell genomics reveals region-specific developmental trajectories underlying neuronal diversity in the human hypothalamus. Sci. Adv. 9, eadf6251 (2023).10.1126/sciadv.adf6251 ↗
12. Vialle, R. A., de Paiva Lopes, K., Bennett, D. A., Crary, J. F. & Raj, T. Integrating whole-genome sequencing with multi-omic data reveals the impact of structural variants on gene regulation in the human brain. Nat. Neurosci. 25, 504–514 (2022).10.1038/s41593-022-01031-7 ↗
13. Yao, Z. et al. A high-resolution transcriptomic and spatial atlas of cell types in the whole mouse brain. Nature 624, 317–332 (2023). This article introduces a collaborative effort from the BRAIN Initiative Cell Census Network, presenting cellular maps of the mouse brain with high spatial resolution.10.1038/s41586-023-06812-z ↗
14. Chini, M. & Hanganu-Opatz, I. L. Prefrontal cortex development in health and disease: lessons from rodents and humans. Trends Neurosci. 44, 227–240 (2021).10.1016/j.tins.2020.10.017 ↗
15. Fu, H., Hardy, J. & Duff, K. E. Selective vulnerability in neurodegenerative diseases. Nat. Neurosci. 21, 1350–1358 (2018). This paper provides a comprehensive overview of the current understanding of biological mechanisms underpinning selective neuronal and regional vulnerability in neurological disorders.10.1038/s41593-018-0221-2 ↗
16. Goodkind, M. et al. Identification of a common neurobiological substrate for mental illness. JAMA Psychiatry 72, 305–315 (2015).10.1001/jamapsychiatry.2014.2206 ↗
17. Del Tredici, K., Rüb, U., De Vos, R. A. I., Bohl, J. R. E. & Braak, H. Where does Parkinson disease pathology begin in the brain? J. Neuropathol. Exp. Neurol. 61, 413–426 (2002).10.1093/jnen/61.5.413 ↗
18. De Marchi, F. et al. Cognitive dysfunction in amyotrophic lateral sclerosis: can we predict it? Neurol. Sci. 42, 2211–2222 (2021).10.1007/s10072-021-05188-0 ↗
19. Crockford, C. et al. ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS. Neurology 91, e1370–e1380 (2018).10.1212/WNL.0000000000006317 ↗
20. Lassmann, H. Multiple sclerosis pathology. Cold Spring Harb. Perspect. Med. 8, a028936 (2018).10.1101/cshperspect.a028936 ↗
21. Haider, L. et al. The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain. Brain 139, 807–815 (2016).10.1093/brain/awv398 ↗
22. Knopman, D. S. et al. Alzheimer disease. Nat. Rev. Dis. Primers 7, 33 (2021).10.1038/s41572-021-00269-y ↗
23. Schöll, M. et al. Biomarkers for tau pathology. Mol. Cell. Neurosci. 97, 18–33 (2019).10.1016/j.mcn.2018.12.001 ↗
24. Musolino, P. L. et al. Brain endothelial dysfunction in cerebral adrenoleukodystrophy. Brain 138, 3206–3220 (2015).10.1093/brain/awv250 ↗
25. Pong, S., Karmacharya, R., Sofman, M., Bishop, J. R. & Lizano, P. The role of brain microvascular endothelial cell and blood-brain barrier dysfunction in schizophrenia. Complex Psychiatry 6, 30–46 (2020).10.1159/000511552 ↗
26. Estudillo, E. et al. Thinking outside the black box: are the brain endothelial cells the new main target in Alzheimer’s disease? Neural Regen. Res. 18, 2592 (2023).10.4103/1673-5374.373672 ↗
27. Yang, A. C. et al. A human brain vascular atlas reveals diverse mediators of Alzheimer’s risk. Nature 603, 885–892 (2022).10.1038/s41586-021-04369-3 ↗
28. Mrdjen, D. et al. The basis of cellular and regional vulnerability in Alzheimer’s disease. Acta Neuropathol. 138, 729–749 (2019).10.1007/s00401-019-02054-4 ↗
29. Bennett, H. C. & Kim, Y. Pericytes across the lifetime in the central nervous system. Front. Cell. Neurosci. 15, 627291 (2021).10.3389/fncel.2021.627291 ↗
30. Giguère, N., Burke Nanni, S. & Trudeau, L.-E. On cell loss and selective vulnerability of neuronal populations in Parkinson’s disease. Front. Neurol. 9, 455 (2018).10.3389/fneur.2018.00455 ↗
31. Mamelak, M. Parkinson’s disease, the dopaminergic neuron and gammahydroxybutyrate. Neurol. Ther. 7, 5–11 (2018).10.1007/s40120-018-0091-2 ↗
32. Reiner, A. & Deng, Y.-P. Disrupted striatal neuron inputs and outputs in Huntington’s disease. CNS Neurosci. Ther. 24, 250–280 (2018).10.1111/cns.12844 ↗
33. Spoleti, E. et al. Dopamine neuron degeneration in the ventral tegmental area causes hippocampal hyperexcitability in experimental Alzheimer’s disease. Mol. Psychiatry 29, 1265–1280 (2024).10.1038/s41380-024-02408-9 ↗
34. Nobili, A. et al. Dopamine neuronal loss contributes to memory and reward dysfunction in a model of Alzheimer’s disease. Nat. Commun. 8, 14727 (2017).10.1038/ncomms14727 ↗
35. Chen, X.-Q. & Mobley, W. C. Exploring the pathogenesis of Alzheimer disease in basal forebrain cholinergic neurons: converging insights from alternative hypotheses. Front. Neurosci. 13, 446 (2019).10.3389/fnins.2019.00446 ↗
36. Baker-Nigh, A. et al. Neuronal amyloid-β accumulation within cholinergic basal forebrain in ageing and Alzheimer’s disease. Brain 138, 1722–1737 (2015).10.1093/brain/awv024 ↗
37. Vana, L. et al. Progression of tau pathology in cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer’s disease. Am. J. Pathol. 179, 2533–2550 (2011).10.1016/j.ajpath.2011.07.044 ↗
38. Tan, R. H. et al. Cerebellar neuronal loss in amyotrophic lateral sclerosis cases with ATXN2 intermediate repeat expansions. Ann. Neurol. 79, 295–305 (2016).10.1002/ana.24565 ↗
39. Fukutani, Y., Cairns, N. J., Rossor, M. N. & Lantos, P. L. Purkinje cell loss and astrocytosis in the cerebellum in familial and sporadic Alzheimer’s disease. Neurosci. Lett. 214, 33–36 (1996).10.1016/0304-3940(96)12875-5 ↗
40. Singh-Bains, M. K. et al. Cerebellar degeneration correlates with motor symptoms in Huntington disease. Ann. Neurol. 85, 396–405 (2019).10.1002/ana.25413 ↗
41. Louis, E. D. et al. Torpedoes in Parkinson’s disease, Alzheimer’s disease, essential tremor, and control brains. Mov. Disord. 24, 1600–1605 (2009).10.1002/mds.22567 ↗
42. Crabé, R., Aimond, F., Gosset, P., Scamps, F. & Raoul, C. How degeneration of cells surrounding motoneurons contributes to amyotrophic lateral sclerosis. Cells 9, 2550 (2020).10.3390/cells9122550 ↗
43. Elgayar, S. A. M., Abdel-Hafez, A. A. M., Gomaa, A. M. S. & Elsherif, R. Vulnerability of glia and vessels of rat substantia nigra in rotenone Parkinson model. Ultrastruct. Pathol. 42, 181–192 (2018).10.1080/01913123.2017.1422066 ↗
44. Cragnolini, A. B. et al. Regional brain susceptibility to neurodegeneration: what is the role of glial cells? Neural Regen. Res. 15, 838–842 (2019).
45. Matute, C., Alberdi, E., Ibarretxe, G. & Sánchez-Gómez, M. V. Excitotoxicity in glial cells. Eur. J. Pharmacol. 447, 239–246 (2002).10.1016/S0014-2999(02)01847-2 ↗
46. Petito, C. K., Olarte, J. P., Roberts, B., Nowak, T. S. & Pulsinelli, W. A. Selective glial vulnerability following transient global ischemia in rat brain. J. Neuropathol. Exp. Neurol. 57, 231–238 (1998).10.1097/00005072-199803000-00004 ↗
47. Kim, Y.-K. & Na, K.-S. Role of glutamate receptors and glial cells in the pathophysiology of treatment-resistant depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 70, 117–126 (2016).10.1016/j.pnpbp.2016.03.009 ↗
48. Giuliani, F., Goodyer, C. G., Antel, J. P. & Yong, V. W. Vulnerability of human neurons to T cell-mediated cytotoxicity. J. Immunol. 171, 368–379 (2003).10.4049/jimmunol.171.1.368 ↗
49. Paß, T., Wiesner, R. J. & Pla-Martín, D. Selective neuron vulnerability in common and rare diseases — mitochondria in the focus. Front. Mol. Biosci. 8, 676187 (2021).10.3389/fmolb.2021.676187 ↗
50. Penzes, P., Buonanno, A., Passafarro, M., Sala, C. & Sweet, R. A. Developmental vulnerability of synapses and circuits associated with neuropsychiatric disorders. J. Neurochem. 126, 165–182 (2013).10.1111/jnc.12261 ↗
51. Purves, D. et al. in Neuroscience 2nd edn Ch. 1 (Sinauer Associates, 2001).
52. Eipel, C., Abshagen, K. & Vollmar, B. Regulation of hepatic blood flow: the hepatic arterial buffer response revisited. World J. Gastroenterol. 16, 6046–6057 (2010).10.3748/wjg.v16.i48.6046 ↗
53. Dalal, R., Bruss, Z. S. & Sehdev, J. S. Physiology, Renal Blood Flow and Filtration (StatPearls, 2023).
54. Cabral, H., Li, J., Miyata, K. & Kataoka, K. Controlling the biodistribution and clearance of nanomedicines. Nat. Rev. Bioeng. 2, 214–232 (2024). This comprehensive review details consequence of different NP designs on their pharmacokinetics, with abundant clinical data included.10.1038/s44222-023-00138-1 ↗
55. Du, B., Yu, M. & Zheng, J. Transport and interactions of nanoparticles in the kidneys. Nat. Rev. Mater. 3, 358–374 (2018).10.1038/s41578-018-0038-3 ↗
56. Wang, J. & Liu, G. Imaging nano–bio interactions in the kidney: toward a better understanding of nanoparticle clearance. Angew. Chem. Int. Ed. 57, 3008–3010 (2018). This review details quantitative NP–kidney interactions along with coverage on strategies to modulate NP size, shape and surface chemistry to minimize glomerular clearance.10.1002/anie.201711705 ↗
57. Rawal, M., Singh, A. & Amiji, M. M. Quality-by-design concepts to improve nanotechnology-based drug development. Pharm. Res. 36, 153 (2019).10.1007/s11095-019-2692-6 ↗
58. Blanco, E., Shen, H. & Ferrari, M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol. 33, 941–951 (2015). This seminal review discusses the design principles of NPs to avoid delivery challenges, with focus on opsonization, blood vessel fluid dynamics and site-directed entry.10.1038/nbt.3330 ↗
59. Park, J.-K. et al. Cellular distribution of injected PLGA-nanoparticles in the liver. Nanomedicine 12, 1365–1374 (2016).10.1016/j.nano.2016.01.013 ↗
60. Poon, W. et al. Elimination pathways of nanoparticles. ACS Nano 13, 5785–5798 (2019).10.1021/acsnano.9b01383 ↗
61. Lazarovits, J. et al. Supervised learning and mass spectrometry predicts the in vivo fate of nanomaterials. ACS Nano 13, 8023–8034 (2019).10.1021/acsnano.9b02774 ↗
62. Anraku, Y., Kishimura, A., Kobayashi, A., Oba, M. & Kataoka, K. Size-controlled long-circulating PICsome as a ruler to measure critical cut-off disposition size into normal and tumor tissues. Chem. Commun. 47, 6054–6056 (2011).10.1039/c1cc11465d ↗
63. Lundqvist, M. et al. The evolution of the protein corona around nanoparticles: a test study. ACS Nano 5, 7503–7509 (2011).10.1021/nn202458g ↗
64. Cai, R. & Chen, C. The crown and the scepter: roles of the protein corona in nanomedicine. Adv. Mater. 31, e1805740 (2019).
65. Monopoli, M. P., Åberg, C., Salvati, A. & Dawson, K. A. Biomolecular coronas provide the biological identity of nanosized materials. Nat. Nanotech 7, 779–786 (2012).10.1038/nnano.2012.207 ↗
66. Lundqvist, M. et al. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc. Natl Acad. Sci. USA 105, 14265–14270 (2008).10.1073/pnas.0805135105 ↗
67. García-Álvarez, R., Hadjidemetriou, M., Sánchez-Iglesias, A., Liz-Marzán, L. M. & Kostarelos, K. In vivo formation of protein corona on gold nanoparticles. The effect of their size and shape. Nanoscale 10, 1256–1264 (2018).10.1039/C7NR08322J ↗
68. Palchetti, S. et al. The protein corona of circulating PEGylated liposomes. Biochim. Biophys. Acta 1858, 189–196 (2016).10.1016/j.bbamem.2015.11.012 ↗
69. Wang, H. et al. The nature of a hard protein corona forming on quantum dots exposed to human blood serum. Small 12, 5836–5844 (2016).10.1002/smll.201602283 ↗
70. Dobrovolskaia, M. A. et al. Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles. Nanomedicine 5, 106–117 (2009).10.1016/j.nano.2008.08.001 ↗
71. Sakulkhu, U., Mahmoudi, M., Maurizi, L., Salaklang, J. & Hofmann, H. Protein corona composition of superparamagnetic iron oxide nanoparticles with various physico-chemical properties and coatings. Sci. Rep. 4, 5020 (2014).10.1038/srep05020 ↗
72. Lesniak, A. et al. Effects of the presence or absence of a protein corona on silica nanoparticle uptake and impact on cells. ACS Nano 6, 5845–5857 (2012).10.1021/nn300223w ↗
73. Liu, K. et al. Multiomics analysis of naturally efficacious lipid nanoparticle coronas reveals high-density lipoprotein is necessary for their function. Nat. Commun. 14, 4007 (2023).
74. Mitchell, M. J. et al. Engineering precision nanoparticles for drug delivery. Nat. Rev. Drug Discov. 20, 101–124 (2021).10.1038/s41573-020-0090-8 ↗
75. Salvati, A. et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat. Nanotech 8, 137–143 (2013).10.1038/nnano.2012.237 ↗
76. Zhao, Z., Ukidve, A., Kim, J. & Mitragotri, S. Targeting strategies for tissue-specific drug delivery. Cell 181, 151–167 (2020).10.1016/j.cell.2020.02.001 ↗
77. Chen, F. et al. Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo. Nat. Nanotech 12, 387–393 (2017).10.1038/nnano.2016.269 ↗
78. Hoshyar, N., Gray, S., Han, H. & Bao, G. The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. Nanomedicine 11, 673–692 (2016).10.2217/nnm.16.5 ↗
79. Moghimi, S. M., Simberg, D., Skotland, T., Yaghmur, A. & Hunter, A. C. The interplay between blood proteins, complement, and macrophages on nanomedicine performance and responses. J. Pharmacol. Exp. Ther. 370, 581–592 (2019).10.1124/jpet.119.258012 ↗
80. Huang, W., Xiao, G., Zhang, Y. & Min, W. Research progress and application opportunities of nanoparticle–protein corona complexes. Biomed. Pharmacother. 139, 111541 (2021).10.1016/j.biopha.2021.111541 ↗
81. Klepac, D. et al. Interaction of spin-labeled HPMA-based nanoparticles with human blood plasma proteins — the introduction of protein-corona-free polymer nanomedicine. Nanoscale 10, 6194–6204 (2018).10.1039/C7NR09355A ↗
82. Müller, K., Fedosov, D. A. & Gompper, G. Margination of micro- and nano-particles in blood flow and its effect on drug delivery. Sci. Rep. 4, 4871 (2014).
83. Lane, L. A. Physics in nanomedicine: phenomena governing the in vivo performance of nanoparticles. Appl. Phys. Rev. 7, 011316 (2020).10.1063/1.5052455 ↗
84. Cooley, M. et al. Influence of particle size and shape on their margination and wall-adhesion: implications in drug delivery vehicle design across nano-to-micro scale. Nanoscale 10, 15350–15364 (2018).10.1039/C8NR04042G ↗
85. Kumar, A., Rivera, R. G. H. & Graham, M. D. Flow-induced segregation in confined multicomponent suspensions: effects of particle size and rigidity. J. Fluid Mech. 738, 423–462 (2014).10.1017/jfm.2013.592 ↗
86. Tosi, G., Duskey, J. T. & Kreuter, J. Nanoparticles as carriers for drug delivery of macromolecules across the blood-brain barrier. Expert Opin. Drug Deliv. 17, 23–32 (2020).10.1080/17425247.2020.1698544 ↗
87. Pandit, R., Chen, L. & Götz, J. The blood-brain barrier: physiology and strategies for drug delivery. Adv. Drug Deliv. Rev. 165–166, 1–14 (2020).10.1016/j.addr.2019.11.009 ↗
88. Arvanitis, C. D., Ferraro, G. B. & Jain, R. K. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. Nat. Rev. Cancer 20, 26–41 (2020).10.1038/s41568-019-0205-x ↗
89. Kucharz, K. et al. Post-capillary venules are the key locus for transcytosis-mediated brain delivery of therapeutic nanoparticles. Nat. Commun. 12, 4121 (2021).10.1038/s41467-021-24323-1 ↗
90. Uchida, Y. et al. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J. Neurochem. 117, 333–345 (2011).10.1111/j.1471-4159.2011.07208.x ↗
91. Yeo, N. J. Y., Chan, E. J. J. & Cheung, C. Choroidal neovascularization: mechanisms of endothelial dysfunction. Front. Pharmacol. 10, 1363 (2019).10.3389/fphar.2019.01363 ↗
92. Sweeney, M. D., Sagare, A. P. & Zlokovic, B. V. Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat. Rev. Neurol. 14, 133–150 (2018). This comprehensive review discusses the BBB dysfunction in multiple neurological disorders using neuroimaging studies in living human and post-mortem brain tissues.10.1038/nrneurol.2017.188 ↗
93. Malek, N. et al. Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson’s disease. Mov. Disord. 31, 1518–1526 (2016).10.1002/mds.26698 ↗
94. Drouin-Ouellet, J. et al. Cerebrovascular and blood-brain barrier impairments in Huntington’s disease: potential implications for its pathophysiology. Ann. Neurol. 78, 160–177 (2015).10.1002/ana.24406 ↗
95. Profaci, C. P., Munji, R. N., Pulido, R. S. & Daneman, R. The blood-brain barrier in health and disease: important unanswered questions. J. Exp. Med. 217, e20190062 (2020).10.1084/jem.20190062 ↗
96. Nguyen, B., Bix, G. & Yao, Y. Basal lamina changes in neurodegenerative disorders. Mol. Neurodegener. 16, 81 (2021).10.1186/s13024-021-00502-y ↗
97. Prakash, R. & Carmichael, S. T. Blood–brain barrier breakdown and neovascularization processes after stroke and traumatic brain injury. Curr. Opin. Neurol. 28, 556–564 (2015).10.1097/WCO.0000000000000248 ↗
98. Price, L., Wilson, C. & Grant, G. in Translational Research in Traumatic Brain Injury Ch. 4 (eds Laskowitz, D. & Grant, G.) (CRC, 2016).
99. Clond, M. A. et al. Reactive oxygen species-activated nanoprodrug of ibuprofen for targeting traumatic brain injury in mice. PLoS ONE 8, e61819 (2013).10.1371/journal.pone.0061819 ↗
100. Xu, J. et al. Theranostic oxygen reactive polymers for treatment of traumatic brain injury. Adv. Funct. Mater. 26, 4124–4133 (2016).10.1002/adfm.201504416 ↗